SNDX Key Statistics, Chart & Performance
The current stock price of SNDX is 21.085 USD. In the past month the price increased by 9.64%. In the past year, price increased by 63.16%.
SNDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.39B | ||
| AMGN | AMGEN INC | 14.85 | 174.84B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.47B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.73 | 117.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.73 | 83.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.57 | 52.59B | ||
| INSM | INSMED INC | N/A | 37.31B | ||
| NTRA | NATERA INC | N/A | 32.36B | ||
| BIIB | BIOGEN INC | 11.19 | 27.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.36 | 20.87B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.79B |
Related stock screener links
About SNDX
Company Profile
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 270 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Company Info
SYNDAX PHARMACEUTICALS INC
730 Third Avenue, 9Th Floor
New York City NEW YORK 02451 US
CEO: Briggs W. Morrison
Employees: 270
Phone: 17814191400
SYNDAX PHARMACEUTICALS INC / SNDX FAQ
What does SNDX do?
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 270 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
What is the current price of SNDX stock?
The current stock price of SNDX is 21.085 USD. The price decreased by -1.43% in the last trading session.
What is the dividend status of SYNDAX PHARMACEUTICALS INC?
SNDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNDX stock?
SNDX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is SNDX stock listed?
SNDX stock is listed on the Nasdaq exchange.
What do analysts say about SYNDAX PHARMACEUTICALS INC (SNDX) stock?
20 analysts have analysed SNDX and the average price target is 40.09 USD. This implies a price increase of 90.15% is expected in the next year compared to the current price of 21.085.
Is SYNDAX PHARMACEUTICALS INC (SNDX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNDX.
SNDX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SNDX. When comparing the yearly performance of all stocks, SNDX is one of the better performing stocks in the market, outperforming 92.28% of all stocks.
SNDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNDX. SNDX has a bad profitability rating. Also its financial health evaluation is rather negative.
SNDX Financial Highlights
Over the last trailing twelve months SNDX reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS increased by 0.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.44% | ||
| ROE | -269.78% | ||
| Debt/Equity | 2.78 |
SNDX Forecast & Estimates
20 analysts have analysed SNDX and the average price target is 40.09 USD. This implies a price increase of 90.15% is expected in the next year compared to the current price of 21.085.
For the next year, analysts expect an EPS growth of 14.66% and a revenue growth 73.17% for SNDX